青光眼滤过术后抗瘢痕化的研究进展
Research progress on anti-scarring after glaucoma filtration surgery
周小钰 1李方芳 1刘倩宏 1姚小磊2
作者信息
- 1. 湖南中医药大学,湖南 长沙 410208;中医药防治眼耳鼻咽喉疾病湖南省重点实验室,湖南 长沙 410208
- 2. 湖南中医药大学第一附属医院,湖南 长沙 410007
- 折叠
摘要
青光眼的典型表现是病理性眼压升高,手术疗法是一种迅速降低眼压的治疗手段.而青光眼滤过手术的成功率与术后抗瘢痕化有密切关系,术后抗瘢痕化成为提高青光眼手术成功率的重要议题.除了传统的抗代谢药物,目前已有新型抗代谢药物、新型分子生物材料、基因材料等,中医药同时也在抗瘢痕化方面有所研究.本文对近年来青光眼滤过术后的抗瘢痕化研究进行综述.
Abstract
The typical manifestation of glaucoma is characterized by a pathological increase in intraocular pressure,and surgical treatment serves as a means of rapidly reducing it.The success rate of glaucoma filtration surgery is closely linked to postoperative anti-scarring,making anti-scarring an important factor in enhancing the success rate of glaucoma surgery.In addition to traditional anti-metabolic drugs,there are also novel anti-metabolic drugs,new molecular biomaterials,genetic materials,etc.At the same time,Chinese medicine has also delved into the study of anti-scar drugs.This paper reviews the recent research on anti-scarring for glaucoma filtration surgery.
关键词
青光眼/抗瘢痕化/青光眼滤过手术/成纤维细胞/抗血管内皮生长因子药物/中药Key words
glaucoma/anti-scarring/glaucoma filtration surgery/fibroblast/anti-vascular endothelial growth factor drugs/Chinese medicines引用本文复制引用
基金项目
湖南省"芙蓉学者"奖励计划(湘人才办[2022]3号)
湖南中医药大学"王衡新科研基金"项目(2023HX007)
湖南省研究生科研创新项目(2023CX45)
湖南省卫生健康委高层次人才计划(2022)()
出版年
2024
国家科技期刊平台
NSTL
万方数据